FIGURE 7.

hnRNPA2B1 and NEAT1 enhanced stemness and promoted chemoresistance via Wnt/β‐catenin pathway in GC. (A) GSEA analysis between hnRNPA2B1^high NEAT1^high group (n = 105) and hnRNPA2B1^low NEAT1^low group (n = 104). (B) Immunoblots of active β‐catenin, β‐catenin, c‐Myc, and cyclin D1 in hnRNPA2B1‐silenced SGC7901^ADR cells, hnRNPA2B1‐silenced SGC7901^VCR cells and hnRNPA2B1‐overexpressed SGC7901 cells cell lines respectively. (C‐D) IC50 values and growth curves of SGC7901^ADR cells after the indicated treatment (ICG‐001, 25 µmol/L for 24 h). (E‐F) IC50 values and growth curves of SGC7901^VCR cells after the indicated treatment (ICG‐001, 25 µmol/L for 24 h). (G) Immunoblots of active β‐catenin, β‐catenin, CD133 and CD44 in SGC7901^VCR cells after the indicated treatment (ICG‐001, 25 µmol/L for 24 h). (H‐I) Representative images (H) and quantification (I) of the sphere‐forming abilities of SGC7901^VCR cells after the indicated treatment. Scale bar, 200 µm. (J) Immunoblots of active β‐catenin, β‐catenin, CD133 and CD44 in SGC7901 cells after the indicated treatment (Wnt3A, 100 ng/mL for 24 h). (K‐L) Representative images (K) and quantification (L) of the sphere‐forming abilities of SGC7901 cells after the indicated treatment. Scale bar, 200 µm. The P value was calculated by two‐way ANOVA test (C‐F), and paired t test (I and L). *P < 0.05, ** P < 0.01, *** P < 0.001. Abbreviations: CD133, cluster of differentiation 133; CD44, cluster of differentiation 44; FDR, false discovery rate; GSEA, gene set enrichment analysis; hnRNPA2B1, heterogeneous nuclear ribonucleoprotein A2B1; lv‐NC, empty overexpression control; lv‐A2B1, overexpression of hnRNPA2B1; NES, normalized enrichment score; P.adj, adjust P value; shNC, negative control short hairpin RNA; shA2B1, short hairpin RNA of hnRNPA2B1.